Aetiology and antibiotic resistance issues regarding urological procedures

References

• Naber KG, Hofstetter AG, Bryhl P, Bichler K, Lebert C. Guidelines for perioperative prophylaxis in interventions of the urinary and male genital tract. Int J Antimicrob Agents. 2001;17(4):321–6.
   PubMed Web of Science ®Google Scholar
• Societé Francaise d’Anesthésie et de Réanimation (SFAR). Recommendations for antibacterial prophylaxis in surgery. Pyrexie. 1999;3:21–30
   Google Scholar
• Naber KG, Schaeffer AJ, Heyns CF, Matsumoto T, Shoskes DA, Bjerklund Johansen TE, et al. Urogenital infections. 1st ed. Arnhem: European Association of Urology; 2010.
   Google Scholar
• Burke JF. The effective period of preventive antibiotic action in experimental incision and dermal lesion. Surgery. 1961;50:161–8.
   PubMed Web of Science ®Google Scholar
• Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. NEJM. 1992;326(5):281–6.
   PubMed Web of Science ®Google Scholar
• Bates T, Siller G, Crathern BC, Bradley SP, Zlotnik RD, Couch C, et al. Timing of prophylactic antibiotics in abdominal surgery: trial of a pre-operative versus an intra-operative first dose. Br J Surg. 1989;76(1):52–6.
   PubMed Web of Science ®Google Scholar
• Cruse PJ, Foord R. The epidemiology of wound infections. A 10-year prospective of 62,939 wounds. Surg Clin North Am. 1980;60(1):27–40.
   PubMed Web of Science ®Google Scholar
• Bjerklund-Johansen TE, Naber K, Tenke P. The PanEuropean prevalence study on nosocomial urinary tract infections. Vienna: European Association of Urology; 2004.
   Google Scholar
• Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000;85(6):682–5.
   PubMed Web of Science ®Google Scholar
• Webb NR, Woo HH. Antibiotic prophylaxis for prostate biopsy. BJU Int. 2002;89(8):824–8.
   PubMed Web of Science ®Google Scholar
• Enlund AL, Varenhorst E. Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases. Br J Urol. 1997;79(5):777–80.
   PubMedGoogle Scholar
• Larsson P, Norming U, Törnblom M, Gustafsson O. Antibiotic prophylaxis for prostate biopsy: benefits and costs. Prostate Cancer Prostatic Dis. 1999;2(2):88–90.
   PubMed Web of Science ®Google Scholar
• Puig J, Darnell A, Bermudez P, Malet A, Serrate G, Baré M, et al. Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary? Eur Radiol. 2006;16(4):939–43.
   PubMed Web of Science ®Google Scholar
• Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology. 1998;52(4):552–8.
   PubMed Web of Science ®Google Scholar
• Isen K, Küpeli B, Slinik Z, Sözen S, Bozkirli I. Antibiotic prophylaxis for transrectal biopsy of the prostate: a prospective randomized study of the prophylacitic use of single dose oral fluoroquinolones versus trimethoptim-sulfamethoxazole. Int Urol Nephrol. 1999;31(4):491–5.
   PubMedGoogle Scholar
• Crawford ED, Haynes AL, Story MW, Borden TA. Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol. 1982;127(3):449–51.
   PubMed Web of Science ®Google Scholar
• Melekos MD. Efficacy of prophylactic antimicrobial regimes in preventing infectious complications after transrectal biopsy of the prostate. Int Urol Nephrol. 1990;22(3):257–62
   PubMedGoogle Scholar
• Briffaux R, Merlet B, Normand G, Coloby P, Leremboure H, Bruyère F, et al. Short or long schemes of antibiotic prophylaxis for prostate biopsy. A multicentre prospective randomized study. Prog Urol. 2009;19(1):39–46.
   PubMed Web of Science ®Google Scholar
• Kraklau DM, Wolf JS Jr. Review of antibiotic prophylaxis recommendations for office-based urologic procedures. Tech Urol. 1999;5(3):123–8.
   PubMedGoogle Scholar
• Wilson L, Ryan J, Thelning C, Masters J, Tuckey J. Is antibiotic prophylaxis required for flexible cystoscopy? A truncated randomized double-blind controlled trial. J Endourol. 2005;19(8):1006–8.
   PubMed Web of Science ®Google Scholar
• Latthe PM, Foon R, Toozs-Hobson P. Prophylactic antibiotics in urodynamics: a systematic review of effectiveness and safety. Neurourol Urodyn. 2008;27(3):167–73.
   PubMed Web of Science ®Google Scholar
• Clark KR, Higgs MJ. Urinary infection following out-patient flexible cystoscopy. Br J Urol. 1990;66(5):503–5.
   PubMedGoogle Scholar
• Almallah YZ, Rennie CD, Stone J, Lancashire MJ. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology. 2000;56(1):37–9.
   PubMed Web of Science ®Google Scholar
• Burke DM, Shackley DC, O’Reilly PH. The community-based morbidity of flexible cystoscopy. BJU Int. 2002;89(4):347–9.
   PubMed Web of Science ®Google Scholar
• Johnson MI, Merrilees D, Robson DA, Lennon T, Masters J, Orr KE. Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. BJU Int. 2007;100(4):826–9.
   PubMed Web of Science ®Google Scholar
• Jimenez Cruz JF, Sanz Chinesta S, Otero G, Díaz González R, Alvarez Ruiz F, Flores N, et al. Antimicrobial prophylaxis in urethrocystoscopy. Comparative study. Actas Urol Esp. 1993;17(3):172–5.
   PubMedGoogle Scholar
• Manson AL. Is antibiotic administration indicated after outpatient cystoscopy. J Urol. 1988;140(2):316–7.
   PubMed Web of Science ®Google Scholar
• Karmouni T, Bensalah K, Alva A, Patard JJ, Lobel B, Guillé F. Role of antibiotic prophylaxis in ambulatory cystoscopy. Prog Urol. 2001;11(6):1239–41.
   PubMed Web of Science ®Google Scholar
• Tsugawa M, Monden K, Nasu Y, Kumon H, Ohmori H. Prospective randomized comparative study of antibiotic porophylaxis in urethrocystoscopy and urethrocystography. Int J Urol. 1998;5(5):441–3.
   PubMedGoogle Scholar
• Cundiff GW, McLennan MT, Bent AE. Randomized trial of antibiotic prophylaxis for combined urodynamics and cystourethroscopy. Obstet Gynecol. 1999;93(5 Pt 1):749–52.
   PubMed Web of Science ®Google Scholar
• Logadottir Y, Dahlstrand C, Fall M, Knutson T, Peeker R. Invasive urodynamic studies are well tolerated by the patients and associated with a low risk of urinary tract infection. Scand J Urol Nephrol. 2001;35(6):459–62.
   PubMedGoogle Scholar
• Wagenlehner FM, Wagenlehner C, Schinzel S, Naber KG; Working Group ‘Urological Infections’ of German Society of Urology. Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate. Eur Urol. 2005;47(4):549–56.
   PubMed Web of Science ®Google Scholar
• Qiang W, Jianchen W, MacDonald R, Monga M, Wilt TJ. Antibiotic prophylaxis for transurethral prostatic resection in men with preoperative urine containing less than 100,000 bacteria per ml: a systematic review. J Urol. 2005;173(4):1175–81.
   PubMed Web of Science ®Google Scholar
• Berry A, Barrat A. Prophylactic antibiotic use in transurethral prostatic resection: a meta-analysis. J Urol. 2002;167(2 Pt 1):571–7.
   PubMed Web of Science ®Google Scholar
• Upton JD, Das S. Prophylactic antibiotic in transurethral resection of bladder tumors: are they necessary? Urology. 1986;27(5):421–3.
   PubMed Web of Science ®Google Scholar
• Delavierre D, Huiban B, Fournier G, Le Gall G, Tande D, Mangin P. The value of antibiotic prophylaxis in transurethral resection of bladder tumors. Apropos of 61 cases. Prog Urol. 1993;3(4):577–82.
   PubMedGoogle Scholar
• Grabe M. Perioperative antibiotic prophylaxis in urology. Curr Opin Urol. 2001;11(1):81–5.
   PubMedGoogle Scholar
• Fourcade RO. Antibiotic prophylaxis with cefotaxime in endoscopic extraction of upper urinary tract stones: a randomized study. The Cefotaxime Cooperative Group. J Antimicrob Chemother. 1990;26(Suppl A):77–83.
   PubMedGoogle Scholar
• Knopf HJ, Graff HJ, Schulze H. Perioperative antibiotic prophylaxis in ureteroscopic stone removal. Eur Urol. 2003;44(1):115–8.
   PubMed Web of Science ®Google Scholar
• Hendrikx AJ, Strijbos WE, de Knijff DW, Kums JJ, Doesburg WH, Lemmens WA. Treatment for extended-mid and distal ureteral stones: SWL or uretheroscopy? Results of a multicenter study. J Endourol. 1999;13(10):727–33.
   PubMed Web of Science ®Google Scholar
• Rao PN, Dube DA, Weightman NC, Oppenheim BA, Morris J. Prediction of septicaemia following endourological manipulation for stones in the upper urinary tract. J Urol. 1991;146:955–60.
   PubMed Web of Science ®Google Scholar
• Charton M, Vallencien G, Veillon B, Brisset JM. Urinary tract infection in percutaneous surgery for renal calculi. J Urol. 1986;135(1): 15–27.
   PubMed Web of Science ®Google Scholar
• Dogan HS, Sahin A, Cetinkaya Y, Akdogan B, Ozden E, Kendi S. Antibiotic prophylaxis in precutaneous nephrolithotomy: prospective study in 81 patients. J Endourol. 2002;16(9):649–53.
   PubMed Web of Science ®Google Scholar
• Deliveliotis C, Giftopoulos A, Koutsokalis H, Raptidis G, Kostakopoulos A. The necessuty of prophylactic antibiotics during extracorporal shock wave lithotripsy. Int Urol Nephrol. 1997;29(5):517–21.
   PubMedGoogle Scholar
• Claes H, Vandeursen R, Baert L. Amoxycillin/Clavulanate prophylaxis for extracorpereal shock wave lithotripsy — a comparative study. J Antimicrob Chemother. 1989;24(Suppl B):217–20.
   PubMedGoogle Scholar
• Pettersson B, Tiselius HG. Are prophylactic antibiotic necessary during extracorporeal shockwave lithotripsy? Br J Urol. 1989;63(5):449–52.
   PubMedGoogle Scholar
• Bierkens AF, Hendrikx AJ, Ezz el Gin KE, de la Rosette JJ, Horrevorts A, Doesburg W, et al. The value of antibiotic prophylaxis during extracorporeal shock wave lithotripsy in the prevention of urinary tract infections in patients with urine proven sterile prior treatment. Eur Urol. 1997;31(1):30–5.
   PubMed Web of Science ®Google Scholar
• Pearle MS, Roehrborn CG. Antimicrobial prophylaxis prior to shock wave lithotripsy in patients with urine sterile urine before treatment: a meta-analysis and cost-effectiveness analysis. Urology. 1997;49(5):679–86
   PubMed Web of Science ®Google Scholar
• Steiner T, Traue C, Schubert J. [Perioperative antibiotic prophylaxis in transperitoneal tumor nephrectomy: does it lower the rate of clinically significant postoperative infections?]. Urologe A. 2003;42(1):34–7. German.
   PubMedGoogle Scholar
• Montgomery JS, Johnston WK 3rd, Wolf JS Jr. Wound complication after hand assisted laparoscopic surgery. J Urol. 2005;174(6):2226–30.
   PubMed Web of Science ®Google Scholar
• Kiddoo DA, Wollin TA, Mador DR. A population based assessment of complications following outpatient hydrocelectomy and spermatolocelectomy. J Urol. 2004;171(2 Pt1): 746–8.
   PubMed Web of Science ®Google Scholar
• Stranne J, Aus G, Hansson C, Lodding P, Pileblad E, Hugosson J. Single-dose orally administered quinolone appears to be sufficient antibiotic prophylaxis for radical retropubic prostatectomy. Scand J Urol Nephrol. 2004;38(2):143–7.
   PubMedGoogle Scholar
• Terai A, Ichioka K, Kohei N, Ueda N, Utsunomiya N, Inoue K. Antibiotic prophylaxis in radical prostatectomy: 1-day versus 4-day treatments. Int J Urol. 2006;13(12):1488–93.
   PubMed Web of Science ®Google Scholar
• Takeyama K, Tkahashi S, Maeda T, Mutoh M, Kunishima Y, Matsukawa M, et al. Comparison of 1-day, 2-day and 3-day administration of antimicrobial prophylaxis in radical prostatectomy. J Infect Chemother. 2007;13(5):320–3.
   PubMedGoogle Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96.
   PubMed Web of Science ®Google Scholar
• Giani T, Pini B, Arena F, Conte V, Bracco S, Migliavacca R, et al. Epidemic diffusion of KPC carbapenemases-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill. 2013;18(22).
   PubMedGoogle Scholar
• Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton D, Zeglinski PT, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant Gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101–5.
   PubMed Web of Science ®Google Scholar
• Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15:e732–9.
   PubMed Web of Science ®Google Scholar
• Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010;29:127–42.
   PubMed Web of Science ®Google Scholar
• Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect. 2011;18:4–7.
   PubMed Web of Science ®Google Scholar
• Periti P, Rizzo M. Ruolo degli antibiotici orali in urologia diagnostica e terapeutica: la fosfomicina trometamolo. Farm Ter (Int J Drugs Ther). 2000;XVII(Suppl 2):3–29.
   Google Scholar
• Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43–50.
   PubMed Web of Science ®Google Scholar
• Carlone NA, Borsotto M, Cuffini AM, Savoia D. Effect of fosfomycin trometamol on bacterial adhesion in comparison with other chemotherapeutic agents. Eur Urol. 1987;13(Suppl 1):86–91.
   PubMedGoogle Scholar
• Albini E, Arena E, Bellucco G, Marca G. Adhesion of bacteria to human uroepithelial cells and bactericidal activity of fosfomycin trometamol. In: Neu HC, Williams JC, editors. New trends in urinary tract infections. The single dose therapy. Basel: Karger; 1988. p. 250–254.
   Google Scholar
• Wagenlehner FM, Thomas PM, Naber KG. Fosfomycin trometamol (3,000 mg) in perioperative antibiotic prophylaxis of healthcare-associated infections after endourological interventions: a narrative review. Urol Int. 2014;;92(2):125–30.
   PubMed Web of Science ®Google Scholar
• Borghi CM, Laveneziana D, Riva A, Marca G, Zannini G. Concentrazioni nel siero e nel tessuto prostatico di fosfomicina con fosfomicina-trometamolo, nuovo derivato della fosfomicina con elevata biodisponibilità per somministrazione orale. Farm Ter (Int J Drugs Ther). 1986;III(3):216–20.
   Google Scholar
• Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56:5744–8.
   PubMed Web of Science ®Google Scholar
• Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extend spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents. 2007;29:62–5.
   PubMed Web of Science ®Google Scholar
• Prakash V, Lewis JS 2nd, Herrera ML, Wickes BL, Jorgensen JH. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2009;53:1278–80.
   PubMed Web of Science ®Google Scholar
• Fournier D, Chirouze C, Leroy J, Cholley P, Talon D, Plésiat P, et al. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal infect. 2013;43:62–6.
   PubMed Web of Science ®Google Scholar
• Jimenez-Pacheco A, Lardelli Claret P, Lopez Luque A, Lahoz-Garcia C, Arrabal Polo MA, Nogueras Ocana M. Randomized clinical trial on antimicrobial prophylaxis for flexible urethrocystoscopy. Arch Esp Urol. 2012;65:542–9.
   PubMed Web of Science ®Google Scholar
• Baert L, Billiet I, Vandepitte J. Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection. Infection. 1990;18(Suppl 2):S103–6.
   PubMedGoogle Scholar
• Nicoletti G, Nicolosi D, Schito GC, Varaldo M, Carati L. Fosfomycin trometamol in prophylaxisof bacteriuria associated with transurethral diagnostic procedures. Urogynaecologia. 1994;8:123–34.
   Google Scholar
• Periti P, Novelli A, Reali EF, del Bono GP, Fontana P. Prophylactic chemotherapy with fosfomycin trometamol salt in transurethral prostatectomy. A controlled clinical trial. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. The Single-Dose Therapy International Symposium. Basel: Karger; 1988. p. 207–233.
   Google Scholar
• di Silverio F, Cruciani E, Ferrone G, Prencipe MG, Lauretti S, Fini D. Evaluation of fosfomycin trometamol in the prevention of urinary tract infections after ESWL and ureteropyeloscopy. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. The Single-Dose Therapy International Symposium. Basel: Karger; 1988. p. 329–332.
   Google Scholar
• di Silverio F, Ferrone G, Carati L. Prophylacticchemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres. Results of a multicentre study. Infection. 1990;18(Suppl 2):S98–102.
   PubMedGoogle Scholar
• Selvaggi FP, Battaglia M, Grossi FS, Disabato G, Cormio L. Oral prophylaxis with fosfomycin trometamol in transurethral prostatectomy and urological maneuvers: literature review and personal experience. Infection. 1992;20(Suppl 4):S321–4.
   PubMedGoogle Scholar
• Szopinski T, Antoniewicz AA, Borówka A. [The prophylactic use of phosphomycin in endoscopic procedures associated urinary tract infections]. Urol Pol. 2002;55:1–7. Polish.
   Google Scholar